Research
Browse or search our latest peer-reviewed research publications.
Identification of Cost-Effectiveness Evidence in UK NICE Single Technology Assessment Company Submissions: Databases, Sources and Currency of Searching
ISPOR US 2024: Poster Session: 1. May 6th 2024. Poster Session Time: 10:30-13:30. Discussion Period: 12:30-13:30.
European Health Technology Assessment: Historical Success of European Joint Assessments
ISPOR US 2024: Poster Session: 1. May 6th 2024. Poster Session Time: 10:30-13:30. Discussion Period: 12:30-13:30.
Systematic Literature Review Requirements for Health Technology Assessment in European Markets
ISPOR US 2024: Poster Session: 3. May 7th 2024. Poster Session Time: 10:30-13:30. Discussion Period: 12:30-13:30.
Comparison of the Use of Real-World Evidence for Clinical Effectiveness in HTA Pre- and Post- Introduction of the NICE Framework – an Update
ISPOR US 2024: Poster Session: 3. May 7th 2024. Poster Session Time: 10:30-13:30. Discussion Period: 12:30-13:30.
A Comparative Assessment of Systematic Literature Review Requirements for Health Technology Assessment, Globally
ISPOR Europe 2023: Poster Session: 5. 15 November 2023. Poster Session Time: 9:00 - 11:30. Discussion Period: 9:00 - 10:00.
Surrogate Endpoints Used in NICE Technology Appraisals for Oncology and Non-Oncology Indications, 2022–23
ISPOR Europe 2023: Poster Session: 1. 13 November 2023. Poster Session Time: 10:30-13:30. Discussion Period: 12:30-13:30.
Comparison of the Use of Real-World Evidence for Clinical Effectiveness in HTA Pre- and Post- Introduction of the NICE Framework
ISPOR Europe 2023: Poster Session: 5. 15 November 2023. Poster Session Time: 9:00-11:30. Discussion Period: 9:00-10:00
Challenges and Solutions to Estimating Environmental Impact in Health Technology Assessment
ISPOR Europe 2023: Poster Session: 4. 14 November 2023. Poster Session Time: 15:30-18:30. Discussion Period: 16:00-17:00
Reducing carbon footprint by switching to reusable soft mist inhalers
Janson C, Platz JH, Soulard S, Langham S, Nicholson L, Hartgers-Gubbels ES. Reducing carbon footprint by switching to reusable soft mist inhalers. ERJ Open Res 2023;9(3):00543-2022.
Clinical characteristics of patients with eosinophilic esophagitis in the UK: a retrospective analysis of the Clinical Practice Research Datalink (CPRD) Database
Xu X, Maslova E, Kielar D, Kwiatek J, Chen S, Stirnadel-Farrant H, et al. Clinical characteristics of patients with eosinophilic esophagitis in the UK: a retrospective analysis of the Clinical Practice Research Datalink (CPRD) Database. Poster number: 269. Presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting; 24–27 February 2023; San Antonio, TX: USA. 2023
Durability of vaccine-induced and natural immunity against COVID-19: a narrative review
Pooley N, Abdool Karim SS, Combadière B, Ooi EE, Harris RC, El Guerche Seblain C, et al. Durability of vaccine-induced and natural immunity against COVID-19: a narrative review. Infect Dis Ther 2023:1-21.
Cost–consequence analysis of COPD treatment according to NICE and GOLD recommendations compared with current clinical practice in the UK
Wright A, Vioix H, de Silva S, Langham S, Cook J, Capstick T, et al. Cost–consequence analysis of COPD treatment according to NICE and GOLD recommendations compared with current clinical practice in the UK. BMJ Open 2022;12(6):e059158.
Hepatitis B surface antigen prevalence and the rates of mother-to-child transmission of hepatitis B virus after the introduction of infant vaccination programs in SE Asia & Western Pacific regions
Marjenberg Z, Wright C, Pooley N, Cheung KW, Shimakawa Y, Vargas-Zambrano JC, et al. Hepatitis B surface antigen prevalence and the rates of mother-to-child transmission of hepatitis B virus after the introduction of infant vaccination programs in South East Asia and Western Pacific regions: a systematic review. Int J Infect Dis 2022;124:65-75.
Costs and clinical consequences of compliance with COPD GOLD recommendations or national guidelines compared with current clinical practice in Belgium, Germany, Sweden, and the United States
Sethi S, Wright A, Hartgers-Gubbels E, Hechtner M, Clark B, Wright C, et al. Costs and clinical consequences of compliance with COPD GOLD recommendations or national guidelines compared with current clinical practice in Belgium, Germany, Sweden, and the United States. Int J Chron Obstruct Pulmon Dis 2022;17:2149-2160.
Rapid evidence publication in the COVID-19 era: impact on study quality and study identification
Wright C, Misso K, Green R, Marjenberg Z. Rapid evidence publication in the COVID-19 era: impact on study quality and study identification (SA43). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022
Trends in clinical evidence for digital health applications (DiGa) reimbursed in the German DiGa directory
Skeldon G, Dobson J, Adkins E. Trends in clinical evidence for digital health applications (DiGa) reimbursed in the German DiGa directory. Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022
The increasing use of population-adjusted indirect comparisons in the NICE Health Technology Assessment (HTA) submission process and the response to these methods
Pooley N, Kisomi M, Embleton N, Langham S. The increasing use of population-adjusted indirect comparisons in the NICE Health Technology Assessment (HTA) submission process and the response to these methods (CO163). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022
Reusable soft mist inhalers have an improved carbon footprint compared with dry powder inhalers and pressurised metered-dose inhalers
Janson C, Hernando Platz J, Soulard S, Langham S, Nicholson L, Hartgers-Gubbels E. Reusable soft mist inhalers have an improved carbon footprint compared with dry powder inhalers and pressurised metered-dose inhalers (HSD2). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022
Treatment with dual and triple therapy in chronic obstructive pulmonary disease in line with current guidelines reduces the carbon footprint
Janson C, Hernando Platz J, Soulard S, Langham S, Nicholson L, Hartgers-Gubbels E. Treatment with dual and triple therapy in chronic obstructive pulmonary disease in line with current guidelines reduces the carbon footprint (MT40). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022